PROF
Profound Medical Corp

393
Mkt Cap
$183.28M
Volume
66,529.00
52W High
$8.75
52W Low
$3.76
PE Ratio
-4.54
PROF Fundamentals
Price
$5.88
Prev Close
$6.07
Open
$6.06
50D MA
$5.56
Beta
0.82
Avg. Volume
76,743.87
EPS (Annual)
-$1.12
P/B
5.70
Rev/Employee
$75,211.27
Loading...
Loading...
News
all
press releases
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·1d ago
News Placeholder
Profound Medical (NASDAQ:PROF) Releases Earnings Results, Beats Estimates By $0.12 EPS
Profound Medical (NASDAQ:PROF - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus...
MarketBeat·5d ago
News Placeholder
Profound Medical (TSE:PRN) Trading Down 0.1% - Here's What Happened
Profound Medical (TSE:PRN) Stock Price Down 0.1% - Here's Why...
MarketBeat·6d ago
News Placeholder
Profound Medical $PROF Shares Purchased by Thompson Davis & CO. Inc.
Thompson Davis & CO. Inc. grew its position in shares of Profound Medical (NASDAQ:PROF - Free Report) by 32.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·6d ago
News Placeholder
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -44.75% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of -20.93% and -25.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -104.20% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest PROF News

View

Advertisement|Remove ads.

Advertisement|Remove ads.